The finding centres on a behaviour called cell traversal. When an infected mosquito bites a host, it injects sporozoites, the parasite’s liver-infective stage, into the skin. These slender, motile parasites enter the bloodstream and travel to the liver, where they must cross the sinusoidal barrier to reach their target hepatocytes. Before doing so, they repeatedly breach the membranes of host cells, glide through the cytoplasm and exit without establishing a lasting infection. This process, first described more than two decades ago, has long been viewed mainly as a mechanical necessity for the parasite’s journey. The new work shows it is also a powerful immunological event, one that shapes the composition and potency of the T cell response that whole-sporozoite vaccines depend upon.

Whole-sporozoite vaccines, which use radiation-attenuated, genetically attenuated or chemically attenuated parasites, are the only malaria vaccine strategy that has consistently achieved sterile protection—the complete prevention of infection—in both rodent models and human trials. This stands in sharp contrast to the licensed subunit vaccines RTS,S and R21, which target the circumsporozoite protein and reduce clinical disease but do not reliably stop infection, a key requirement for eradication. The prevailing assumption has been that whole-sporozoite protection depends primarily on the immunizing parasites infecting hepatocytes and undergoing prolonged intrahepatic development, thereby exposing the host to a broad repertoire of parasite antigens. The Lisbon team set out to test whether that assumption told the whole story.

To do so, the researchers compared wild-type Plasmodium berghei parasites with genetically engineered lines unable to perform cell traversal. One line lacked the SPECT1 protein, a sporozoite microneme component essential for breaching host cell membranes; a second, newly generated line lacked the perforin-like protein PLP1, which serves a similar function. Because traversal-deficient parasites are also less infectious, the team carefully calibrated inoculum sizes, establishing that a fifteen-fold higher dose of the mutant parasites produced liver infection loads equivalent to those achieved with the standard dose of wild-type parasites. Crucially, the mutants retained normal gliding motility and, once inside hepatocytes, developed normally, meaning any difference in vaccine efficacy could be attributed specifically to the loss of traversal rather than to a general defect in parasite fitness.

The results were striking. In a standard prime–boost–boost immunization regimen with radiation-attenuated sporozoites, roughly 82.5 percent of mice vaccinated with wild-type parasites were completely protected against subsequent challenge with infectious parasites, showing no blood-stage infection over a twelve-day monitoring period. Among mice vaccinated with the traversal-deficient parasites, however, protection collapsed: none of the SPECT1-deficient cohort and only about 13 percent of the PLP1-deficient cohort remained parasite-free. The pattern held even under immunization regimens that allowed extended or complete intrahepatic development, using infectious sporozoites under azithromycin or chloroquine chemoprophylaxis. Even when the mutant parasites replicated fully in the liver, they failed to confer sterilizing immunity. Conversely, parasites lacking the P36p protein—which cannot develop substantially in the liver but retain full traversal ability—protected mice just as effectively as wild-type parasites, with comparable durability over nearly seven months.

These findings decouple protection from productive intrahepatic development and reposition parasite behaviour as a central immunogenic determinant. But what mechanism underlies this effect? The team found that antibody responses were largely intact in mice vaccinated with traversal-deficient parasites: anti-sporozoite IgG levels rose comparably in all immunized groups, regardless of the parasites’ ability to traverse cells or develop in the liver. The deficit lay specifically in cellular immunity. In C57BL/6 mice, a strain in which protection depends on CD8 T cells clearing infected hepatocytes, traversal-deficient vaccination failed to generate the protective T cell response. When the researchers depleted CD8 T cells from wild-type-vaccinated C57BL/6 mice before challenge, protection vanished entirely, confirming the dominant role of these cells. In BALB/c mice, a strain that mounts strong antibody-mediated responses, both wild-type and traversal-deficient parasites conferred full protection, and CD8 T cell depletion had no effect—demonstrating that traversal matters precisely when protection relies on T cells.

Using high-parameter spectral flow cytometry and unsupervised clustering of liver leukocytes, the researchers then identified the specific cell population affected. Mice vaccinated with traversal-competent parasites showed a marked expansion of CD8 tissue-resident memory T cells, or TRM cells, in the liver—cells bearing the hallmark markers CD69 and KLRG1-negative status, along with high CXCR3 and CXCR6 expression and elevated CD127 and PD-1, consistent with long-lived, antigen-experienced residents. These cells were significantly under-represented in mice vaccinated with traversal-deficient parasites. Liver-resident memory CD8 T cells are known to form a front-line defence against malaria liver-stage infection, and their presence correlates with durable protection. The team also found that these cells persisted in the liver at least seventy-five days after priming, matching the window of robust protection observed in challenge experiments.

Delving deeper into antigen specificity, the researchers examined CD8 TRM cells targeting two well-characterized Plasmodium epitopes: PbTRAP, a thrombospondin-related protein expressed mainly at the sporozoite stage and shed during parasite locomotion, and PbRPL6, a ribosomal protein associated with intrahepatic development. Vaccination with traversal-competent parasites expanded TRM cells specific for both epitopes. Traversal-deficient vaccination, however, selectively compromised the TRAP-specific population while leaving RPL6-specific cells detectable, albeit reduced. This selective loss suggests that traversal amplifies responses against sporozoite-derived antigens in particular, plausibly by disseminating parasite material across many host cells early in infection. Notably, the defect was not explained by reduced TRAP shedding during gliding motility, and splenectomy experiments showed that while splenic priming contributes to the overall magnitude of the hepatic TRM pool, traversal at the site of infection independently shapes its antigen-specific composition.

The implications for vaccine design are substantial. Current efforts have focused overwhelmingly on identifying optimal antigens and epitopes; this study argues that the dynamic interactions between the parasite and host tissues deserve equal attention. Next-generation whole-sporozoite vaccines might be engineered or selected for enhanced traversal motility to promote stronger, longer-lasting liver-resident CD8 TRM responses. Alternatively, the molecular and inflammatory cues generated by cell traversal could inspire adjuvants that mimic its immunostimulatory effects, potentially benefiting subunit vaccines that currently rely on humoral immunity alone. The findings may also help explain why responses to whole-sporozoite vaccines in humans are heterogeneous, with some vaccinees failing to achieve sterile protection for reasons that remain poorly understood.

There is also an evolutionary dimension worth pondering. It may seem paradoxical that a parasite evolved a behaviour that ultimately arms the immune system against it. The authors suggest this represents a trade-off: under natural transmission, only a small number of sporozoites reach the liver, and traversal is essential for crossing the skin and sinusoidal barriers to establish infection at all. The immunostimulatory consequences only become decisive during vaccination, when artificially high parasite doses amplify exposure to traversal-dependent cues. Whether this principle—harnessing parasite behaviour rather than merely parasite antigens—can be translated into human vaccines remains an open question, particularly since liver-resident T cells are difficult to sample directly in people. Still, the study marks a conceptual shift: for malaria, how a parasite moves through its host may matter as much as what it is made of.

Subject of Research: The role of Plasmodium sporozoite host cell traversal in inducing sterilizing CD8 T cell-mediated immunity after whole-sporozoite malaria vaccination

Article Title: Host cell traversal by Plasmodium parasites drives sterilizing T cell-mediated immunity following immunization

Article References: Rodrigues, A., Mendes, A. M., Gonçalves, R., Nunes-Cabaço, H., Marques, S., Valente-Leal, N., Gomes da Costa, D., Ferreira, C., Veldhoen, M., Prudêncio, M., Mota, M. M., & Chora, Â. F. (2026). Host cell traversal by Plasmodium parasites drives sterilizing T cell-mediated immunity following immunization. Nature Microbiology. https://doi.org/10.1038/s41564-026-02477-2

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02477-2

Keywords: malaria, Plasmodium, sporozoites, cell traversal, T cells, tissue-resident memory T cells, vaccines, liver-stage immunity, CD8 T cells, radiation-attenuated sporozoites, immunology, Nature Microbiology

T cells sit at the heart of adaptive immunity. Each one carries a T cell receptor generated by random recombination of gene segments, producing a repertoire of staggering diversity that can, in principle, recognize virtually any peptide fragment displayed on major histocompatibility complex molecules. When a T cell encounters its cognate peptide-MHC complex presented by an infected or malignant cell, it becomes activated, proliferates and executes effector functions such as cytokine secretion or direct killing. Because antigen-specific T cells typically exist at very low frequencies in peripheral blood, and because they are enormously heterogeneous in phenotype, function and receptor sequence, quantifying them accurately has challenged immunologists for decades. The new review emphasizes that no single assay can capture the full picture, and that the choice of method fundamentally shapes what a study can and cannot conclude.

The oldest approaches in the field rely on functional readouts of bulk cell populations. Lymphocyte proliferation assays, dating back to the 1970s, measure how many T cells divide in response to antigen stimulation, originally using radioactive tritiated thymidine incorporation and later shifting to fluorescent dyes such as CFSE that allow division tracking by flow cytometry. Cytotoxicity assays, most famously the chromium-51 release assay introduced in 1968, quantify the killing of labeled target cells. These methods remain informative for assessing whether a T cell population can proliferate or kill, but they provide little information about which cells are responsible, what phenotype they carry, or how they relate to protective immunity. The review notes that dye-based proliferation assays and their radioactive predecessors can differ in sensitivity for low-frequency responses, and that modern modifications preserve cell viability while enabling spectral flow cytometry analysis.

The enzyme-linked immunospot, or ELISPOT, assay transformed the field by allowing direct enumeration of individual antigen-reactive cells. Developed originally in 1983 to count antibody-secreting cells and adapted for T cell cytokines, ELISPOT detects the footprints of secreted molecules such as interferon-gamma on a membrane, with each spot corresponding to a single responding cell. Its sensitivity, relative simplicity and suitability for large clinical trials made it a workhorse of vaccine immunology, from hepatitis B studies in the 1990s through the massive COVID-19 vaccine programs, where it helped document T cell responses to BNT162b1 and booster regimens. The review highlights that decades of proficiency panels run by the Cancer Vaccine Consortium and harmonization guidelines for automated spot evaluation have made ELISPOT one of the most standardized functional assays available. Its extension, FluoroSpot, permits simultaneous detection of multiple cytokines, revealing polyfunctional response profiles that correlate more closely with protective immunity than single-cytokine counts.

Flow cytometry brought a decisive leap in information content. Intracellular cytokine staining, enabled by protein transport inhibitors such as brefeldin A, allows researchers to identify which T cells produce which cytokines while simultaneously measuring dozens of surface markers. The review traces the maturation of this approach from early two-color experiments through validated eight-color assays optimized for vaccine trials, up to contemporary spectral flow cytometry panels that approach fifty parameters. Alongside cytokine readouts, activation-induced marker assays exploit the upregulation of surface molecules such as CD154, CD137, OX40, CD25 and CD69 after antigen encounter. Because these markers appear without requiring intracellular fixation, they allow viable sorting of antigen-specific cells for downstream expansion or sequencing. The review notes that AIM assays have proven particularly valuable for detecting rare CD4 T cell responses, including those to SARS-CoV-2, that conventional cytokine assays miss, and that recent automated workflows have improved their reproducibility across laboratories.

Perhaps the most direct way to identify an antigen-specific T cell is to bind it with a soluble mimic of its ligand. Peptide-MHC multimers, introduced with tetramers in 1996, achieve this by clustering fluorescently labeled peptide-MHC complexes so that the low-affinity T cell receptor interaction becomes stable enough for detection. The review documents the steady engineering of these reagents: reversible multimers that can be stripped from cells after staining, conditional MHC ligands that allow on-demand peptide loading, dodecamers with enhanced avidity, affinity-matured class II reagents for robust CD4 staining, and combinatorial encoding schemes that pool dozens of differently labeled multimers in a single tube. DNA-barcoded multimers push the concept further, enabling screening of hundreds of specificities simultaneously by sequencing rather than fluorescence. Applied to COVID-19, malaria, celiac disease and cancer neoantigens, multimer staining provides phenotypic depth that functional assays cannot match, though it requires knowledge of the epitope and the restricting HLA allele.

High-throughput sequencing of T cell receptors has opened an entirely orthogonal window on antigen-specific immunity. Rather than interrogating function or ligand binding, repertoire sequencing catalogs the receptor sequences themselves, revealing clonal expansions, shared public clonotypes and convergent responses across individuals. The review discusses the technical challenges that once limited this approach, including biases among sequencing platforms and the difficulty of pairing alpha and beta chains, and describes solutions ranging from unique molecular identifiers to single-cell methods that link receptor sequence with transcriptome. Computational tools such as GLIPH2 and tcrdist3 cluster receptors by sequence similarity to predict shared specificity, enabling antigen discovery from repertoire data alone. The authors emphasize that sequencing reveals which clones expanded but not what they do, making it most powerful when combined with functional or phenotypic assays on the same cells.

Single-cell multiomics now fuses these dimensions. Methods that pair TCR sequencing with single-cell RNA profiling allow researchers to perform reverse phenotyping, inferring antigen specificity from receptor sequence while simultaneously reading out the transcriptional state of each cell. The review cites applications ranging from identifying SARS-CoV-2-reactive T cell signatures to distinguishing tumor-reactive from bystander clonotypes in pancreatic cancer and brain metastases. Spatial technologies extend the analysis into tissue, with imaging mass cytometry, multiplex immunohistochemistry and spatially resolved TCR sequencing mapping where specific clonotypes reside within tumors and lymphoid structures. These approaches matter because blood-based monitoring may not reflect what happens at the site of disease, and because the spatial organization of immune cells increasingly predicts immunotherapy response, as demonstrated by the clinically validated Immunoscore in colon cancer.

Underlying all of these technologies is a set of preanalytical variables that the review treats with unusual rigor. How blood is drawn, how peripheral blood mononuclear cells are isolated, how samples are cryopreserved and thawed, which culture medium and serum are used, and how long samples sit before stimulation can each swing assay results dramatically. Validation studies have shown that optimized PBMC processing enhances detected response rates in HIV vaccine trials, that serum-free media support consistent ELISPOT performance, and that suboptimal freezing conditions can render samples unusable. The authors argue that careful sample handling is not a technical footnote but a determinant of whether an immunomonitoring program generates trustworthy data, and they call for cell fitness criteria and standardized operating procedures to be adopted broadly.

The review’s central message is one of complementarity rather than competition. Functional assays such as ELISPOT and intracellular cytokine staining answer whether T cells respond and what they secrete; activation-induced marker assays capture viable responding cells across the full repertoire; multimer staining delivers phenotype and frequency with single-epitope resolution; and sequencing connects specificity with clonal architecture and transcriptomic state. Harmonization efforts, from the MIATA reporting guidelines to international proficiency panels for ELISPOT, ICS and multimer assays, have progressively made results comparable across laboratories, a prerequisite for using immune biomarkers as endpoints in clinical trials. As personalized neoantigen vaccines, TCR-engineered cell therapies and mRNA platforms multiply, the authors conclude that thoughtful, multi-assay immunomonitoring, built on standardized sample handling and validated protocols, will remain the foundation for understanding and improving T cell-mediated immunity in the clinic.

Subject of Research: Comparative analysis of traditional and novel laboratory methods for quantifying and characterizing human antigen-specific T cells in immunomonitoring

Article Title: T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells

Article References: Lazzaro, S., Leroux-Roels, G., Janetzki, S., Salaun, B., Cook, L., Franke, K., Poschke, I., Bunse, L., Welters, M. J. P., Fehlings, M., Pattyn, S., Waerlop, G., Brix, L., Tubo, N. J., Molldrem, J. J., Denninger, V., van Esch, W. J. E., Kristensen, N. P., Mahnke, Y. D., … Koch, S. D. (2026). T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells. Nature Protocols. https://doi.org/10.1038/s41596-026-01453-8

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01453-8

Keywords: T cells, immunomonitoring, ELISPOT, flow cytometry, peptide-MHC multimers, T cell receptor sequencing, single-cell multiomics, vaccines, cancer immunotherapy, assay harmonization, cytokines, antigen specificity

The scale of the problem is difficult to overstate. Across the world, there are close to 300 million cases of malaria and almost 400 million dengue infections every year. Malaria is a serious, life-threatening disease caused by a parasite that is typically spread to humans through the bites of infected female Anopheles mosquitoes. Dengue, by contrast, is caused by a virus transmitted through the bites of infected female Aedes mosquitoes. The two diseases share a vector-borne mode of transmission but differ profoundly in their biology, their geography and, as the review makes clear, their recent trajectories.

Lead researcher Dr Toby Cumming, a research fellow in the Health and Climate Initiative at the Monash School of Public Health and Preventive Medicine, said properly understanding the drivers of disease transmission is key to identifying effective public health responses. The review, he argued, is an attempt to untangle the complex web of conditions, climatic and otherwise, that determine where mosquitoes thrive, where parasites and viruses circulate, and where human populations are exposed.

The climatic logic is straightforward in outline, even if it is complicated in detail. As climate change increases temperatures and alters rainfall patterns, this expands the areas with climatic conditions in which Anopheles and Aedes mosquito populations can thrive, Dr Cumming said. Temperature influences every stage of a mosquito’s life cycle, from the speed of larval development to adult survival, and it also governs the rate at which pathogens mature inside the insect. Warmer conditions can shorten the extrinsic incubation period of a virus or parasite, meaning a mosquito that picks up an infection becomes infectious sooner and is more likely to pass it on before it dies. Rainfall, meanwhile, determines the availability of the standing water in which mosquitoes breed, although the relationship is far from simple, since drought can concentrate breeding sites and heavy rain can flush them away.

Those complications matter, and the researchers are careful to emphasise them. The influence of climate factors on transmission is non-linear, effects are seasonal, and there is substantial local variability, meaning that a single global projection can obscure sharply different outcomes from one valley, city or country to the next. Yet despite this complexity, the review notes that warming and shifting rainfall have broadly similar impacts on malaria and dengue transmission, pushing both diseases into regions where they were previously rare or absent and intensifying transmission where conditions are already favourable.

Here the story takes a turn that the authors describe as crucial for policy. Over the last century, during a time of unambiguous warming, rates of malaria have declined while rates of dengue have risen, Dr Cumming said. If climate were the only force at work, such divergence would be hard to explain. The fact that it occurred anyway tells us something important: human interventions and human settlement patterns can overwhelm, redirect or amplify climatic signals, sometimes in opposite directions for two diseases carried by related insects.

The review highlights the non-climate factors that help explain these different trajectories. Mosquito control interventions and drug therapies have driven major gains in reducing malaria transmission. Insecticide-treated bed nets, indoor residual spraying, artemisinin-based combination therapies and rapid diagnostic tests have, over decades, pushed malaria out of large parts of the world where it once flourished, including much of Europe and North America. Dengue has enjoyed no such success. Increasing urbanisation has favoured Aedes mosquitoes, which breed in small man-made containers, thrive in dense tropical cities and bite during the day, and hence the spread of dengue, for which no therapeutics are available. Treatment for dengue is largely supportive, which means that prevention, rather than cure, carries the full weight of controlling the disease.

Dr Cumming emphasised that there is no room for complacency on the malaria front either. Although malaria is in long-term decline, global incidence has risen 8.5 per cent over the past decade, a reversal that coincides with challenges including funding shortfalls, drug and insecticide resistance, conflict and displacement in endemic regions. Recent malaria trends and the rapid growth in dengue are both serious concerns, and we must escalate our prevention and control efforts, he said. The warning is that gains built over a century can erode quickly, particularly as climate change expands the climatic envelope in which transmission is possible.

Against this backdrop, novel preventive interventions for dengue are emerging. Vaccines are now part of the toolkit, and innovative vector control strategies are showing promise, most notably the introduction of the bacterium Wolbachia into Aedes mosquito populations. Wolbachia reduces the mosquitoes’ ability to transmit dengue, and the strategy has been developed by the World Mosquito Program, a not-for-profit group of companies owned by Monash University. When Wolbachia-carrying males and females establish themselves in a wild population, they pass the bacterium to their offspring, and the virus-blocking effect spreads with them, offering a self-sustaining form of biological control that does not depend on repeated insecticide application. Such approaches, combined with the gradual arrival of dengue vaccines, mark a shift in the epidemiology of a disease that has long outpaced medical countermeasures.

Ultimately, the research reinforces the need for a coordinated approach, encompassing interventions to address the many climate and non-climate factors that contribute to the spread of mosquito-borne disease, Dr Cumming said. That coordination spans several domains at once: sustained vector control and surveillance, deployment of vaccines and drugs where they exist, urban planning and water management that reduce Aedes breeding habitat, and, at the global scale, cutting greenhouse gas emissions to limit the warming that is steadily redrawing the map of mosquito-borne risk. The review’s implicit conclusion is that climate change is not a sentence of inevitable escalation. The century of divergence between malaria and dengue demonstrates that human action, whether through bed nets and medicines or through unplanned urban growth, can shape disease outcomes as powerfully as any weather pattern. The task now, the authors argue, is to apply that lesson deliberately, before the combined pressures of warming temperatures, expanding mosquito ranges and growing urban populations tip the balance the other way.

Subject of Research: Climate change impacts on malaria and dengue transmission and prevention strategies

Article Title: Itching for a solution: Addressing mosquito-borne disease as climate change bites

Article References: Itching for a solution: Addressing mosquito-borne disease as climate change bites. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: malaria, dengue, climate change, mosquito-borne disease, vector control, Wolbachia, Aedes, Anopheles, vaccines, urbanisation, public health, Science Advances

At their core, VLPs are self-assembling nanostructures built from viral coat proteins that spontaneously organize into capsids closely resembling native virions in size, symmetry, and surface topology. Because the genetic blueprint of the virus is absent or deliberately removed, these particles cannot replicate or cause infection, which makes them inherently safer than attenuated or inactivated virus preparations. That safety, however, does not come at the cost of immunological potency. The repetitive, multivalent display of epitopes on a nanoscale scaffold is a pattern the immune system evolved to recognize as a hallmark of viral threat, so VLPs are taken up efficiently by antigen-presenting cells and can elicit strong antibody responses, often without the need for aggressive adjuvant formulation. The review emphasizes that this structure-property relationship, the link between capsid architecture and immune outcome, is the central design principle governing everything VLPs do.

The authors classify VLPs along several axes, distinguishing enveloped from non-enveloped particles, simple capsids from multi-layered architectures, and particles derived from bacteriophages, plant viruses, and animal viruses. Each structural class brings distinct advantages. Bacteriophage-derived platforms such as those based on Qβ or MS2 are extraordinarily robust and easy to produce in bacterial expression systems, while plant virus-derived particles offer remarkable stability and low manufacturing cost. Mammalian virus-derived VLPs, including those modeled on hepatitis B core antigen or papillomavirus capsids, more closely mimic the glycosylation and conformational presentation of human pathogens. The choice of scaffold is therefore never neutral: it determines particle size, surface chemistry, cargo capacity, and the nature of the immune response the particle will provoke.

Production is where much of the practical complexity lies. The review systematically compares expression systems, from bacteria and yeast to insect cells, plants, and mammalian cell lines, and it is explicit about the trade-offs. Bacterial systems are fast and cheap but cannot perform the post-translational modifications that some VLPs require; mammalian systems offer authentic glycosylation but at higher cost and lower yield. Glycosylation emerges as a recurring theme, because sugar patterns on capsid proteins can alter both antigenicity and manufacturing consistency. Downstream, purification must control impurities such as host-cell proteins, nucleic acids, and misassembled capsid species, and characterization demands a battery of methods, including electron microscopy, dynamic light scattering, mass spectrometry, and potency assays, to establish the critical quality attributes that regulators will scrutinize.

One of the most consequential sections of the review addresses cargo loading, the set of strategies by which VLPs are transformed from empty shells into delivery vehicles. Cargo can be packaged inside the capsid cavity, covalently or non-covalently attached to the interior or exterior surface, or electrostatically condensed within the particle. Genetic fusion during expression allows peptides and proteins to be displayed on the capsid surface with atomic precision, while chemical conjugation after purification offers flexibility for attaching haptens, drugs, or imaging agents. Disassembly-reassembly protocols exploit the reversible self-assembly of many capsids to trap molecules inside. These engineering options are what allow a single structural platform to serve as a vaccine carrier, a drug delivery vehicle, or a contrast agent, depending on what it carries and how it is decorated.

The clinical track record for prophylactic vaccines provides the field’s strongest precedent. Licensed VLP-based vaccines against hepatitis B virus and human papillomavirus have demonstrated that self-assembling capsids can protect millions of people, and the HPV vaccines in particular showed how multivalent capsid display can generate antibody titers far exceeding those produced by natural infection. The review is careful, however, to separate these established successes from the newer applications that remain largely preclinical or in early translational stages. Therapeutic cancer vaccines built on VLP scaffolds, mRNA delivery systems, CRISPR/Cas genome-editing cargo, and AI-assisted capsid design are all presented as promising but unproven at scale, and the authors resist the temptation to extrapolate from prophylactic success to therapeutic promise without evidence.

That distinction matters because the requirements for therapeutic applications are fundamentally different from those for prophylaxis. A cancer immunotherapy built on a VLP must not only present tumor-associated antigens but also break immune tolerance, often requiring co-delivered adjuvants or checkpoint modulation, and it must navigate an immunosuppressed tumor microenvironment. Gene and RNA delivery demands that particles protect fragile nucleic acid cargo from nucleases, achieve cell-type-specific targeting through surface ligands, and release their payload inside the correct intracellular compartment. For CRISPR/Cas delivery, the cargo is not merely large but enzymatically active, adding constraints on loading efficiency and release kinetics that no licensed VLP product has yet had to satisfy. The review treats each of these modalities as a distinct engineering problem rather than a simple extension of vaccine technology.

Biohybrid and composite design represents the direction the field is heading. The authors describe capsid engineering through rational mutation and directed evolution, surface functionalization with polymers such as PEG to extend circulation time, lipid envelope modification to mimic natural virions, and the incorporation of inorganic or polymeric materials to create composite particles with tailored mechanical and optical properties. These hybrid constructs blur the boundary between a biological nanoparticle and a designed material, which is precisely why the review appears in a journal devoted to composites and hybrid materials. Artificial intelligence is beginning to accelerate this design cycle, with computational models used to predict assembly behavior, optimize epitope presentation, and screen surface modifications, although the review notes that AI-assisted designs remain at an early stage of validation.

Diagnostics and imaging complete the application portfolio. VLPs can serve as high-density antigen displays in serological assays, improving sensitivity by presenting target epitopes in the multivalent arrangement antibodies preferentially recognize. When loaded with contrast agents or fluorophores, they become targeted imaging probes whose capsid provides both stability and molecular specificity. The uniformity of VLP dimensions, typically tens of nanometers, also makes them attractive standards for calibrating nanoscale measurement techniques. In all of these uses, the same core properties recur: self-assembly, monodispersity, programmable surface chemistry, and the absence of infectivity.

The review closes with a sober assessment of what stands between the current state of the art and routine clinical use. Manufacturing complexity, batch-to-batch consistency, glycosylation control, particle stability during storage, and scalability of production are identified as the principal barriers, compounded by a regulatory landscape that has not fully harmonized standards for products that are simultaneously biologicals, drugs, and devices. Potency assays must reliably predict clinical performance, and comparability studies must demonstrate that process changes do not alter critical quality attributes. The authors’ central argument is that the clinical value of VLPs will be determined not by any single breakthrough but by reproducible design, validated characterization, scalable production, and evidence-based implementation. In framing VLPs as biohybrid nanomaterials rather than merely as vaccines, the review offers a unifying conceptual framework for a technology that has already saved lives and may, if its manufacturing and regulatory challenges are met, reshape how vaccines, gene therapies, and precision medicines are built.

Subject of Research: Virus-like particles as biohybrid nanomaterial platforms for vaccines, drug and gene delivery, and diagnostics

Article Title: Virus-like particles as a unifying platform bridging prophylaxis, precision medicine, and advanced therapeutic modalities

Article References: Rasouli, M., Farhadi Khoozani, M., Fallahhosseini, N., Azary, H., ZiaRazzaz, M., Shirovi, S., & Doroudian, M. (2026). Virus-like particles as a unifying platform bridging prophylaxis, precision medicine, and advanced therapeutic modalities. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02050-9

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02050-9

Keywords: virus-like particles, VLPs, vaccines, drug delivery, gene delivery, CRISPR, mRNA delivery, cancer immunotherapy, nanoparticles, biohybrid materials, biomanufacturing, capsid engineering

At Penn State, chemical engineering doctoral candidate Shreya Kapila, working in the laboratory of Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering, is tackling the problem at the level of the membrane surface itself. Her approach is deceptively simple: she modifies the surface properties of the membranes used to sterile filter pharmaceutical products and remove bioburden, the population of living microorganisms that must be eliminated before a drug can be considered safe. The work, published in Biotechnology Journal under the title Modulating Membrane Surface Properties via Prewetting With Polysorbate 20 to Improve Sterile Filtration of Nanoemulsions, demonstrates that a modest change in how a membrane is prepared can yield improvements in filtration capacity of more than a hundredfold in some cases.

To understand why that matters, it helps to consider what pharmaceutical products are actually up against. As Kapila explains, drug products can become contaminated with microorganisms such as bacteria and fungi, particulate matter, and other impurities introduced at different steps in manufacturing. For injectable drug products, sterility is especially critical because the product is administered directly into the patient’s body, bypassing nearly every natural defense the human body possesses. Microbial contamination in an injection can have serious, sometimes fatal, consequences, which is why regulators treat parenteral products, medicines delivered by injection, infusion or implantation, with exceptional scrutiny.

Achieving that level of safety, however, cannot come at the expense of the medicine itself. Manufacturers rely on multiple layers of control: controlled manufacturing environments, sterilized equipment, validated cleaning procedures, and processes specifically designed to prevent or remove microorganisms. At the same time, processing must not damage the product. The goal, Kapila emphasizes, is not only to achieve sterility but to preserve the chemical, physical and functional properties of the drug, including its purity, potency, physical stability, and particle or droplet size. A sterilization process that destroys every microorganism but degrades the active ingredient, or alters the size distribution of droplets in a formulation, has failed on its own terms.

The menu of available sterilization methods reflects this tension. Traditional heat sterilization can rapidly and effectively destroy microorganisms, but it is unsuitable for products that are sensitive to elevated temperatures, an increasingly common problem as biotechnology-derived medicines proliferate. Gamma irradiation offers strong penetration and can be useful for certain heat-sensitive materials, but it may degrade some formulations, including nanoemulsions, liquid formulations containing extremely small oil droplets typically ranging from roughly 20 to 200 nanometers, by increasing droplet size or otherwise destabilizing the product. Chemical sterilization may be appropriate for specific materials and applications. Aseptic processing, in which the drug is assembled from sterile components in a sterile environment, requires extensive facility validation, specialized equipment and strict personnel procedures, making it so complex and costly that manufacturers generally treat it as the last resort.

That leaves sterile filtration as the workhorse for many sensitive liquid products, including vaccines and injectable formulations with fragile active pharmaceutical ingredients. In this process, the drug product is passed through a sterilizing-grade membrane engineered to retain microorganisms while letting the therapeutic molecules or droplets pass through. The method sounds elegant, but it carries its own economic hazards. Some product inevitably remains trapped in the filter or the tubing, and when the active ingredient is expensive or available only in limited quantities, even modest losses translate into substantial financial cost. Time and cost also vary greatly across sterilization approaches; some processes are completed relatively quickly while others demand extended processing, preparation and validation, and heat-sensitive products may require specialized equipment or multi-facility aseptic operations that drive expenses higher still.

Kapila’s research focuses on the intersection of these problems: understanding, at a fundamental level, the factors that govern how nanoemulsions behave as they pass through sterilizing-grade filters. Nanoemulsions are increasingly important as platforms for vaccines and other therapeutic products, yet their tiny oil droplets are vulnerable to fouling phenomena that conventional filtration models do not fully capture. By developing a mechanistic understanding of droplet-membrane interactions, her group aims to improve existing manufacturing practices and address emerging challenges in the production of nanoemulsion-based medicines, connecting fundamental chemical engineering directly to an industry-relevant problem.

The centerpiece of the published work is a strategy that could hardly be easier to implement: prewetting the membrane surface with polysorbate 20, a common surfactant, to increase its hydrophilicity. The results were striking. Prewetting reduced pore blockage, improved the flow of nanoemulsion through the membrane, and increased filter capacity substantially, by more than 100-fold in some cases. In an industry where a single batch of a biologic can be worth millions of dollars, an intervention that multiplies the volume of product a single filter can process, while simultaneously reducing product retained in the filter, represents both a safety and an economic win. As Kapila notes, these findings show that relatively simple surface modification strategies can remarkably improve filtration efficiency and product yield.

The research also illustrates how academic-industrial collaboration can accelerate solutions to manufacturing problems. Kapila joined Zydney’s group at a time when it was working with Merck on a real-world challenge in pharmaceutical manufacturing, an experience she credits with allowing her to study membrane filtration from both a scientific and an applied perspective and to contribute to research directly relevant to pharmaceutical development. She later completed a five-month co-op at GlaxoSmithKline, gaining hands-on experience applying technical knowledge in an industry setting and deepening her understanding of how pharmaceutical manufacturing actually operates at scale.

Beyond the laboratory and the plant floor, Kapila has presented her work at symposia hosted by Penn State’s J. Jeffrey and Ann Marie Fox Graduate School and the Robert V. Waltemeyer Department of Chemical Engineering, and at several international conferences, sharing her findings with researchers and professionals from around the world. She has served as a teaching assistant and mentored undergraduate researchers, experiences she says sharpened her communication, organization and collaboration skills while reinforcing how fundamental research can ultimately make pharmaceutical manufacturing more efficient, more reliable and more capable of delivering safe products to patients. In a field where the difference between a clean membrane and a fouled one can be measured in lives as well as dollars, that pipeline from bench science to bedside safety has rarely mattered more.

Subject of Research: Surface modification of sterilizing-grade filtration membranes to improve sterile filtration of pharmaceutical nanoemulsions

Article Title: Q&A: The safety and sterilization of pharmaceuticals manufacturing

Article References: Q&A: The safety and sterilization of pharmaceuticals manufacturing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sterile filtration, pharmaceutical manufacturing, membrane technology, nanoemulsions, polysorbate 20, aseptic processing, bioburden, drug safety, vaccines, surface modification, Biotechnology Journal, Penn State

Attenuated sporozoites, the infective stage of Plasmodium parasites injected by mosquitoes, have been tested as vaccines for decades because they provoke robust adaptive immunity that protects against subsequent challenge. The most advanced of these approaches, whole-sporozoite vaccines designed to protect through hepatic CD8 T cell immunity, have shown encouraging results in clinical trials. Yet a fundamental question has lingered: how do these parasites engage the innate immune system to license such potent T cell responses? Pattern recognition receptors such as Toll-like receptors and inflammasome sensors are the canonical gatekeepers of innate immunity, but their role in sporozoite immunogenicity has never been clearly defined.

To answer this, the team built what they describe as a reductionist system. They generated fluorescent GFP-expressing Plasmodium berghei and Plasmodium falciparum sporozoites, purified the parasites by flow cytometry directly from mosquito salivary glands, and sorted them onto mouse bone marrow-derived macrophages or human peripheral blood mononuclear cells. This allowed them to isolate the innate response to sporozoites from the confounding signals of mosquito saliva, blood-stage parasites, and other contaminants that complicate whole-organism studies. They then profiled the responding cells using bulk and single-cell RNA sequencing, capturing the transcriptional landscape of innate activation at high resolution.

The results were striking. Sporozoites did not induce the classical inflammatory programs associated with microbial pattern recognition. Instead, the transcriptional signature in macrophages and human monocytes resembled a cell wounding response, the program that cells mount when their plasma membrane is breached. This makes biological sense: sporozoites must traverse host cells as they migrate from the skin through the dermis to the liver, breaching the membranes of the cells they pass through before finally settling in hepatocytes. The parasites, in effect, leave a trail of wounded cells, and the immune system reads that trail as a danger signal.

The evidence for this interpretation came from a decisive genetic experiment. The researchers used sporozoites lacking SPECT1, a protein with a membrane attack complex-like domain that is essential for pore formation and cell traversal. These traversal-deficient parasites, which can still invade hepatocytes but cannot punch through intermediate cells, failed to activate bone marrow-derived macrophages in vitro. The wounding signature disappeared entirely when the pore-forming machinery was removed, demonstrating that the innate activation was not triggered by parasite molecules detected by conventional sensors but by the physical damage the parasite inflicts on host cells.

Importantly, the wounding response was independent of both inflammasome and Toll-like receptor signalling, the two most intensively studied pathways of innate immune activation. This rules out the standard explanation and points instead toward a distinct sensing modality. Previous work from other laboratories has shown that cells surviving sublethal plasma membrane injury mount a characteristic transcriptional response involving repair machinery and chemokine production, and the sporozoite-induced signature overlapped with these curated plasma membrane injury gene sets. The immune system, it appears, can detect the wound itself rather than the weapon that caused it.

The study then connected this innate sensing to the adaptive immunity that actually protects against malaria. In mice immunized with traversal-deficient irradiated sporozoites, the priming of protective CD8 T cell responses was markedly impaired compared with immunization using normal traversal-competent parasites. Given that CD8 T cells are the critical mediators of sterile immunity against the liver stage of malaria, this deficit is not a minor detail. It suggests that the wounding of host cells during traversal is not incidental damage but an essential adjuvant-like signal that the whole-sporozoite vaccine platform depends upon.

A further layer of the mechanism involves γδ T cells, an unconventional lymphocyte population that bridges innate and adaptive immunity. The researchers found that the sensing of cell traversal required γδ T cells, which are already known to support CD8 T cell responses against Plasmodium. Earlier work has shown that γδ T cells are required for the induction of sterile immunity during irradiated sporozoite vaccination, and recent studies have demonstrated that γδ T cell-derived IL-4 can initiate CD8 T cell immunity. The new findings place these cells squarely within the sensing pathway: they appear to translate the cell wounding signal into help for the CD8 T cells that will later eliminate infected hepatocytes.

The cross-species consistency of the results strengthens their significance. Human monocytes exposed to Plasmodium falciparum sporozoites showed an activation pattern that overlapped with the mouse data, including the plasma membrane injury signature, indicating that the mechanism is not a rodent-specific curiosity but likely operates in human malaria infection and vaccination. Single-cell RNA sequencing of human peripheral blood mononuclear cells revealed that multiple innate cell types respond to sporozoites, with the response distinguishable from that induced by blood-stage parasites, which instead triggered more conventional inflammatory programs.

For vaccine development, the implications are considerable. Subunit vaccines based on the circumsporozoite protein have struggled to achieve the high levels of protection seen with whole sporozoites, and this study offers a possible explanation: they lack the cell traversal signal that recruits γδ T cells and licenses potent CD8 T cell priming. Incorporating a wounding-mimetic adjuvant, or designing vaccine delivery strategies that reproduce the membrane injury signal, could help close that gap. Conversely, the findings caution that any attenuated sporozoite vaccine engineered to block traversal, however attractive from a safety standpoint, might sacrifice immunogenicity. As malaria continues to claim hundreds of thousands of lives each year, understanding why live sporozoites are such effective teachers of the immune system brings the field one step closer to a vaccine that can match that performance without a live parasite.

Subject of Research: Innate immune sensing of Plasmodium sporozoite cell traversal and its role in priming protective CD8 T cell responses

Article Title: Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses

Article References: Pohl, K. G., Gao, X., McGowan, J., Mukherjee, P., Le, S., Carreira, P., Ngo, C., Sutton, H. J., Brumhard, S., Hiller, A., Kelly, H. G., Liow, L., Lo, A., Henze, L., Loyal, L., Amino, R., Man, S. M., Beattie, L., Sander, L. E., & Cockburn, I. A. (2026). Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses. Nature Microbiology. https://doi.org/10.1038/s41564-026-02460-x

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02460-x

Keywords: malaria, Plasmodium, sporozoites, cell traversal, innate immunity, CD8 T cells, gamma delta T cells, vaccines, plasma membrane injury, Nature Microbiology, immunology, parasitology

Virus-like particles, often abbreviated as VLPs, are engineered or natural assemblies that mimic the architecture of true viruses but lack any genetic cargo and therefore cannot replicate or cause infection. They occupy a special place in modern biotechnology. Because they present the same repetitive protein lattice that the immune system encounters on a genuine viral surface, they are exceptionally potent platforms for vaccines, and several of the most successful immunizations in current use are built on VLP scaffolds. They are also widely used as delivery vehicles in gene therapy and as programmable nanocontainers in materials science. Understanding how these shells assemble is therefore not a purely academic question; it determines how efficiently such particles can be manufactured, how stable they are once formed, and how their surfaces can be modified for medical applications.

The central difficulty in studying self-assembly has always been one of scale and speed. A complete viral shell, or capsid, is typically built from sixty to several hundred copies of a single capsid protein, and the assembly reaction can pass through fleeting intermediates that exist for microseconds or less. Conventional structural biology techniques excel at determining the static structure of the finished particle. X-ray crystallography and cryo-electron microscopy can render the final capsid at near-atomic resolution, revealing the precise contacts that hold the shell together. But these methods average over enormous numbers of particles and freeze the ensemble at one point in its history. What they cannot easily show is the route by which the components travel from a disorganized solution of subunits to the finished, closed shell.

The new study addresses that gap by following the assembly reaction at the level of individual molecules. The researchers combined advanced single-particle imaging with time-resolved structural analysis, allowing them to observe the same population of virus-like particles as they progressed through distinct assembly stages. Rather than reconstructing a single averaged picture, the approach preserved the heterogeneity of the reaction, exposing the coexistence of half-formed intermediates, partially closed shells, and completed particles at any given moment. This heterogeneity is not noise; it is the physical signature of the assembly pathway itself, and capturing it is what makes a mechanistic reading of the process possible.

From these observations, a coherent picture of the assembly mechanism emerges. The capsid protein does not appear to be a passive brick that simply clicks into place wherever it collides with a growing shell. Instead, the experiments indicate that the subunit adopts distinct conformational states as it participates in the reaction, and that transitions between these states are coupled to the binding events that extend the shell. Early in assembly, small clusters of subunits nucleate the process, overcoming an energetic barrier that must be crossed before growth becomes favorable. Once a stable nucleus exists, the addition of further subunits proceeds rapidly, with each incoming protein locking into the lattice and, in doing so, preorganizing the binding surface for the next arrival.

This coupling between structure and binding is a hallmark of what biophysicists call a nucleation-and-growth mechanism, and it explains both the speed and the specificity of viral assembly. If subunits could bind indiscriminately, misassembled and malformed particles would dominate the reaction. Instead, the observed pathway funnels the components toward the correct geometry. The intermediate states captured in the study show that incorrect associations are either short-lived or structurally primed to convert into productive arrangements, so that the reaction is continually steered back onto the correct trajectory. The result is a yield of properly formed particles that would be the envy of any synthetic chemist, achieved without any external template or instruction beyond the information encoded in the protein sequence itself.

The energetic logic of the process is as important as its structural choreography. Capsid assembly must balance two opposing forces: the favorable contacts between subunits that drive the shell to grow, and the cost of conformational changes and electrostatic interactions that must be paid along the way. Too weak an attraction, and the reaction stalls before a nucleus forms. Too strong, and subunits aggregate irreversibly into useless clumps. The observations reported in Nature suggest that the virus-like particle sits at a finely tuned point between these extremes, with subunit binding affinities and conformational transitions calibrated so that assembly is both efficient and reversible enough to correct local errors. This principle of kinetically regulated, error-correcting self-assembly is one that researchers in nanotechnology have long tried to emulate in synthetic systems, and the direct structural evidence for how a biological assembly achieves it is likely to inform those efforts.

Beyond its fundamental interest, the study carries practical weight for biomedicine. Vaccine manufacturers producing VLP-based immunizations depend on assembly reactions that proceed with high yield and high uniformity, since misassembled particles can compromise both the potency and the safety profile of a product. A mechanistic understanding of the assembly pathway provides rational levers for optimization: adjusting solution conditions, protein sequence, or the presence of cofactors can shift the reaction toward faster nucleation, more stable intermediates, or improved final yield, depending on what the manufacturing process requires. Similarly, in gene therapy and drug delivery, where VLPs and related particles are engineered to encapsulate therapeutic cargo, the timing and coupling of assembly relative to cargo loading is a critical design parameter. The ability to see which intermediates form, and when, turns what has been a largely empirical optimization exercise into an evidence-guided engineering problem.

The work also illustrates a broader shift in structural biology. The field has traditionally been dominated by the determination of static, high-resolution structures of purified, stable states. Increasingly, however, the most pressing questions concern dynamics: how molecular machines move, how signaling proteins switch states, and how supramolecular assemblies build themselves. Methods that can resolve conformational heterogeneity and connect it to reaction progress are transforming those questions from matters of inference into matters of direct observation. In the case of virus-like particles, the application of such methods bridges a long-standing divide between virology, which has emphasized the architecture of mature viruses, and biophysics, which has modeled assembly largely through theory and simulation. Direct structural data on intermediates now provide the empirical anchor that theoretical models of self-assembly have needed.

The demonstration that a virus-like particle can be watched as it assembles, stage by stage, at molecular resolution closes one of the enduring gaps in the understanding of biological self-organization. The finished capsid, so elegant in its symmetry, is revealed not as a structure that simply exists but as the endpoint of a tightly controlled kinetic journey, one in which each subunit both responds to and shapes the assembly around it. For virologists, the findings deepen the picture of how the simplest biological entities achieve such remarkable reliability with so few components. For biotechnologists, they supply a mechanistic foundation for designing and producing the next generation of VLP-based vaccines, delivery vehicles, and nanomaterials. And for the wider study of molecular self-assembly, they offer a vivid reminder that the most sophisticated construction projects in the world are carried out, continuously and invisibly, by molecules following rules that science is only now learning to observe directly.

Subject of Research: Molecular-level observation of the self-assembly pathway of a virus-like particle

Article Title: Molecular-level observation of the self-assembly of a virus-like particle

Article References: Asor, R., Loewenthal, D., Melnyk, D., Tan, T. K., & Kukura, P. (2026). Molecular-level observation of the self-assembly of a virus-like particle. Nature, 657(8132), 653-660. https://doi.org/10.1038/s41586-026-10948-z

Image Credits: AI Generated

DOI: 10.1038/s41586-026-10948-z

Keywords: virus-like particle, self-assembly, capsid, virology, structural biology, biophysics, nucleation and growth, vaccines, nanotechnology, molecular imaging, Molecular-level, observation